Stein Murray B, Stein Dan J
Department of Psychiatry, University of California San Diego 92093-0855, USA.
Lancet. 2008 Mar 29;371(9618):1115-25. doi: 10.1016/S0140-6736(08)60488-2.
Our understanding of social anxiety disorder (also known as social phobia) has moved from rudimentary awareness that it is not merely shyness to a much more sophisticated appreciation of its prevalence, its chronic and pernicious nature, and its neurobiological underpinnings. Social anxiety disorder is the most common anxiety disorder; it has an early age of onset--by age 11 years in about 50% and by age 20 years in about 80% of individuals--and it is a risk factor for subsequent depressive illness and substance abuse. Functional neuroimaging studies point to increased activity in amygdala and insula in patients with social anxiety disorder, and genetic studies are increasingly focusing on this and other (eg, personality trait neuroticism) core phenotypes to identify risk loci. A range of effective cognitive behavioural and pharmacological treatments for children and adults now exists; the challenges lie in optimum integration and dissemination of these treatments, and learning how to help the 30-40% of patients for whom treatment does not work.
我们对社交焦虑障碍(也称为社交恐惧症)的理解已从最初认为它不仅仅是害羞,发展到对其患病率、慢性和有害性质以及神经生物学基础有了更为深入的认识。社交焦虑障碍是最常见的焦虑症;它发病较早——约50%的患者在11岁前发病,约80%的患者在20岁前发病——并且是后续发生抑郁症和药物滥用的一个风险因素。功能性神经影像学研究表明,社交焦虑障碍患者的杏仁核和脑岛活动增加,遗传学研究也越来越关注这一核心表型以及其他(如人格特质神经质)核心表型,以确定风险基因座。现在有一系列针对儿童和成人的有效认知行为治疗和药物治疗方法;挑战在于如何优化整合和推广这些治疗方法,以及了解如何帮助那30%至40%治疗无效的患者。